Category Archives: Stem Cell Treatment


Moving story of bone marrow donor’s amazing 30 year bond with the man he saved – Mirror Online

There was a head-scratching moment when Martin Swales answered his front door and a priest handed him a letter.

The mystery was quickly solved. It contained a thank you note from someone whose life Martin had saved.

He knew his bone marrow had been given to someone called Jan and imagined it was a woman in Britain.

In fact the recipient was dad Jan Zemek 4,500 miles away in the US.

And Martins gift of life has led to an extraordinary 30-year bond between the pair, who are like blood brothers.

Jan named his second daughter Martina in honour of his hero and Martin is godfather to his third girl.

Retired welder Martin, 58, of Guisborough, North Yorks, said: Donating bone marrow didnt just save Jans life, it changed mine as well.

The first time I met Jan, I put my arms around him and he hugged me back.

It felt natural, like I was welcoming my brother. It feels like our two families have become one.

They each have three grown-up children and have visited each other for baptisms, graduations, and weddings.

Martin recently went to Switzerland, where Jan lives with his family, to celebrate 30 years since the transplant and present his blood brother with a Walk of Fame plaque.

It includes the touching message: Stood strong, fought hard, and won. You are a survivor.

The mens amazing and heart-warming story dates from 1986 when Martin joined the Anthony Nolan stem cell register after an appeal to save two girls living in the North East.

He was not a match for the girls but in 1989 was called by the register because he could be for Jan.

Martin said: It was quite a shock because Id pretty much forgotten about the register. They told me I was a possible match for someone and what was involved. I said yes straight away. I wanted to help if I could.

Despite the discomfort, Martin gave bone marrow from his hip at a clinic in Harley Street that August. Doctors extracted it from inside his hip using a long needle. Today most donations are no more invasive than giving blood.

Martin spent two nights in hospital. He said: It doesnt take long but at the time I was suffering from sciatica so I think I found it a bit more painful than most. It was an uncomfortable journey home on the train.Anthony Nolan covered the cost of the trip.

Jan, a 27-year-old dad, was diagnosed with leukaemia in 1987. Initially doctors kept the news from him as no treatment was available in the Czech Republic, where he lived.

Jan said: I was diagnosed one year after the Chernobyl tragedy, weve never known if that radiation was to blame for my cancer. I suddenly grew very tired, nobody knew the reason.

I didnt know how sick I was because the doctors wouldnt tell me.

My wife, who was then my girlfriend, went to the same doctors and they told her, Dont marry this guy, dont have children with him. He is going to die in two years.

But Radka ignored their warning and insisted on marrying Jan in 1987.

His only hope was a bone marrow transplant. Weeks later he left for the US with his dad, who planned to be his donor.

Jan said: A few months earlier, I read in the paper the opera singer Jos Carreras was diagnosed with a similar blood disease and was going to the same US centre for a transplant.

They arrived with less than 40 in their pockets and discovered a transplant from his dad would give Jan only a 15 per cent chance of survival.

Instead doctors advised them to find a donor. It took two years and 10,000 to test potential donors before they found a perfect match in Martin.

By then Jan and Radka had become parents to their first daughter, Jana.

Jan needed to raise more than 100,000 to fund the transplant.

He said: It was such a huge amount of money to raise but when you are dying you have no choice.

There were 12 rival local radio stations but they all got together to run a joint appeal, which they broadcast at the same time. It was incredible.

Jan did a sponsored run, gave talks about his ordeal to church congregations to request donations, and wrote to celebrities, especially those with links to the Czech Republic.

Donald Trump s ex-wife Ivana gave 1,000, as did One Flew Over the Cuckoos Nest director Milos Forman. Jan said: The response was crazy. So many people donated 20 dollars or 50.

Martins bone marrow was flown to the Fred Hutchinson Cancer Research Center in Seattle, where Jan was waiting in an isolation room.

He had been blasted with chemo and radiotherapy so his immune system would not attack Martins transplanted cells.

Normally, under strict anonymity rules to protect donor and recipient, Martin and Jan would have been unable to contact each other for years.

But a priest from the North East of England working at the hospital recognised Martins address when the bag of bone marrow arrived.

He offered to take a photo of Jan, a thank you letter, and a Czech garnet stone to Martin when he returned home in 1990.

Martin said: I was stunned. I had no idea my bone marrow had travelled so far. Knowing Id helped a young father, just like me, brought home how important it was and how easily it could have been me waiting for a stranger to save my life.

I wrote straight back. The priest also brought a letter from a couple whose daughter was in the same hospital.

Her transplant didnt work. Sadly she died, but they wrote to thank me for saving Jan. Responding to them was much harder. How do you find the right words?

Martin and Jan kept in touch. When Jans second daughter was born in 1991, he and Radka named her after Martin.

Jan said: How do you repay someone who saved your life? Naming our daughter after Martin was our way of showing him we would never forget what he did for us.

Hes not just the man who saved my life. He is a nice guy. Thats why were so close.

Video Unavailable

Click to playTap to play

Play now

Jan, 59, and his family moved to Switzerland, where he landed a job with a sports marketing firm that works with World Athletics.

In 1992 his job brought him to Crystal Palace in South London and he spent a few days with Martin and family.

Jans youngest daughter Michaela was born in 1995 and he invited Martin and his family to Switzerland for the baptism and asked him to be godfather.

The two families continued to visit each other and holidayed together in the Czech capital Prague. When Jans eldest, Jana, was studying at Newcastle University, she regularly spent weekends with Martin and his wife Tracey.

Martin said: It meant so much to visit Jan for the 30 anniversary of his transplant earlier this year.

"They showed us the sights and we went up the mountains. It was brilliant. I could never have imagined this when I joined the stem cell register all those years ago.

He added: I hope Martin and I will be able to celebrate another anniversary together in ten years.

The Anthony Nolan register matches potential donors to patients needing stem cell transplants and does vital research. To join, donate or find out more, see anthonynolan.org .

Read more:
Moving story of bone marrow donor's amazing 30 year bond with the man he saved - Mirror Online

Stem Cell Therapy for Osteoarthritis Market Report by Manufacturers, Regions, Type and Application Forecast 2019 2025 – Info Street Wire

Stem Cell Therapy for Osteoarthritis Market primary data collection was achieved by interviewing the retailers and the consumers. The interviews were conducted through one to one structured questionnaire supervision.

Global Stem Cell Therapy for Osteoarthritis Market report provides an in-depth analysis of all market dynamics including drivers and restraints, and trends and opportunities. Important factors supporting growth across various is also provided. Using the industrial figures, the market finds growth figures between the forecast timespan.

Request Exclusive Free Sample PDF Of This Report At https://dataintelo.com/request-sample/?reportId=80747

In order to present an executive-level model of the market and its future perspectives, Stem Cell Therapy for Osteoarthritis Market report presents a clear segmentation based on different parameters. The factors that affect these segments are also discussed in detail in the report.

Major Players included in this report are as follows MesoblastRegeneusU.S. Stem CellAnterogenAsterias Biotherapeutics

To purchase this report, Visit https://dataintelo.com/checkout/?reportId=80747

Stem Cell Therapy for Osteoarthritis Market can be segmented into Product Types as MonotherapyCombination Therapy

Stem Cell Therapy for Osteoarthritis Market can be segmented into Applications as Osteoarthritis (unspecified)Knee OsteoarthritisShoulder OsteoarthritisHip Osteoarthritis

Stem Cell Therapy for Osteoarthritis Market: Regional analysis includes:Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)Europe (Turkey, Germany, Russia UK, Italy, France, etc.)North America (United States, Mexico, and Canada.)South America (Brazil etc.)The Middle East and Africa (GCC Countries and Egypt.)

For More Information on this report, Request Inquiry At https://dataintelo.com/enquiry-before-buying/?reportId=80747

The research provides answers to the following key questions: What is the global (North America, South America, Europe, Africa, Middle East, Asia, China, Japan) production, production value, consumption, consumption value, import and export of Stem Cell Therapy for Osteoarthritis? Who are the global key manufacturers of Stem Cell Therapy for Osteoarthritis industry? How are their operating situation (capacity, production, price, cost, gross and revenue)? What are the types and applications of Stem Cell Therapy for Osteoarthritis? What is the market share of each type and application? What are the upstream raw materials and manufacturing equipment of Stem Cell Therapy for Osteoarthritis? What is the manufacturing process of Stem Cell Therapy for Osteoarthritis? Economic impact on Stem Cell Therapy for Osteoarthritis industry and development trend of Stem Cell Therapy for Osteoarthritis industry. What will the Stem Cell Therapy for Osteoarthritis Market size and the growth rate be in 2025? What are the key factors driving the global Stem Cell Therapy for Osteoarthritis industry? What are the key market trends impacting the growth of the Stem Cell Therapy for Osteoarthritis Market? What is the Stem Cell Therapy for Osteoarthritis Market challenges to market growth? What are the Stem Cell Therapy for Osteoarthritis Market opportunities and threats faced by the vendors in the global Stem Cell Therapy for Osteoarthritis Market?

Stem Cell Therapy for Osteoarthritis Market track and analyse competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, research and developments, with respect to the current market size and future prospective.

For Best Discount on purchasing this report, Visit https://dataintelo.com/ask-for-discount/?reportId=80747

About DataIntelo:DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry.Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info Name Alex MathewsPhone +1 909 545 6473Email [emailprotected]Website https://dataintelo.comAddress 500 East E Street, Ontario, CA 91764, United States.

This post was originally published on Info Street Wire

More here:
Stem Cell Therapy for Osteoarthritis Market Report by Manufacturers, Regions, Type and Application Forecast 2019 2025 - Info Street Wire

MorphoSys Announces Submission of Biologics License Application for Tafasitamab in r/r DLBCL to the FDA | Antibodies | News Channels -…

DetailsCategory: AntibodiesPublished on Monday, 30 December 2019 14:42Hits: 67

PLANEGG/MUNICH, Germany I December 30, 2019 I MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) announced today that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for tafasitamab, an anti-CD19 antibody, for the treatment of relapsed or refractory diffuse large B cell lymphoma (r/r DLBCL). The BLA submission is based on the primary analysis data from the L-MIND trial of tafasitamab in combination with lenalidomide in patients with r/r DLBCL and the retrospective observational matched control cohort Re-MIND evaluating efficacy outcomes of r/r DLBCL patients who received lenalidomide monotherapy.

"The BLA submission marks a significant milestone in MorphoSys' history and demonstrates our dedication to address the high medical need in relapsed or refractory DLBCL," said Dr. Malte Peters, Chief Development Officer of MorphoSys. "If approved, tafasitamab and lenalidomide could become an alternative treatment option for patients with this serious disease."

The FDA has a 60-day filing review period to determine whether the BLA is complete and acceptable for filing. MorphoSys will communicate the agency's decision.

About L-MINDL-MIND is a single arm, open-label phase 2 study, investigating the combination of tafasitamab and lenalidomide in patients with relapsed or refractory diffuse large B cell lymphoma (r/r DLBCL) after up to two prior lines of therapy, including an anti-CD20 targeting therapy (e.g. rituximab), who are not eligible for high-dose chemotherapy and subsequent autologous stem cell transplantation. The study's primary endpoint is objective response rate (ORR). Secondary outcome measures include duration of response (DoR), progression-free survival (PFS) and overall survival (OS). In May 2019, the study reached its primary completion. Primary analysis data with a cut-off date of November 30, 2018 included 80 patients enrolled into the trial who had received tafasitamab and lenalidomide and had been followed-up as per protocol for at least one year. Efficacy results in this update were based on response rates assessed by an independent review committee for all 80 patients. Based on earlier reported interim data from L-MIND, in October 2017 the U.S. FDA granted Breakthrough Therapy Designation for tafasitamab plus lenalidomide in this patient population.

About Re-MINDRe-MIND, an observational retrospective study, was designed to isolate the contribution of tafasitamab in the combination with lenalidomide and to prove the combinatorial effect. The study compares real-world response data of patients with relapsed or refractory DLBCL who received lenalidomide monotherapy with the efficacy outcomes of the tafasitamab-lenalidomide combination, as investigated in MorphoSys's L-MIND trial. Re-MIND collected the efficacy data from 490 r/r DLBCL patients in the U.S. and EU. Qualification criteria for matching patients of both studies were pre-specified. As a result, 76 eligible Re-MIND patients were identified and matched 1:1 to 76 of 80 L-MIND patients based on important baseline characteristics. Objective response rates (ORR) were validated based on this subset of 76 patients in Re-MIND and L-MIND, respectively. The primary endpoint of Re-MIND has been met and shows a statistically significant superior best ORR of the tafasitamab/lenalidomide combination compared to lenalidomide monotherapy.

About tafasitamab (MOR208)Tafasitamab (MOR208) is an investigational humanized Fc-engineered monoclonal antibody directed against CD19. Fc-modification of tafasitamab is intended to lead to a significant potentiation of antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), thus aiming to improve a key mechanism of tumor cell killing. Tafasitamab has been observed in preclinical models to induce direct apoptosis by binding to CD19, which is assumed to be involved in B cell receptor (BCR) signaling.MorphoSys is clinically investigating tafasitamab as a therapeutic option in B cell malignancies in a number of ongoing combination trials. An open-label phase 2 combination trial (L-MIND study) is investigating the safety and efficacy of tafasitamab in combination with lenalidomide in patients with relapsed/refractory DLBCL who are not eligible for high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT). Based on interim data from L-MIND, in October 2017 the U.S. FDA granted Breakthrough Therapy Designation for tafasitamab plus lenalidomide in this patient population. Re-MIND, the real-world data lenalidomide alone matched control cohort met its primary endpoint in October 2019, demonstrating clinical superiority of the tafasitamab/lenalidomide combination compared to lenalidomide alone. The ongoing phase 3 study B-MIND assesses the combination of tafasitamab and bendamustine versus rituximab and bendamustine in r/r DLBCL. In addition, tafasitamab is currently being investigated in patients with relapsed/refractory CLL/SLL after discontinuation of a prior Bruton tyrosine kinase (BTK) inhibitor therapy (e.g. ibrutinib) in combination with idelalisib or venetoclax.

About MorphoSysMorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases. The focus is on cancer. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 28 are currently in clinical development. In 2017, Tremfya(R), marketed by Janssen for the treatment of plaque psoriasis, became the first drug based on MorphoSys's antibody technology to receive regulatory approval. The Company's most advanced proprietary product candidate, tafasitamab (MOR208), has been granted U.S. FDA breakthrough therapy designation for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., has approximately 405 employees. More information at https://www.morphosys.com.

SOURCE: Morphosys

Read the original:
MorphoSys Announces Submission of Biologics License Application for Tafasitamab in r/r DLBCL to the FDA | Antibodies | News Channels -...

All the feels: From start to finish, a year of emotional stories – Golf Channel

No matter how packed with all that makes the game greata golf year might be and Id contend that theres never been a year that wasnt it wont stand out in history unless it has one extra special moment. And 2019 had that.

Golfs broad strokes rarely cut as wide a swath through culture as the Big 3 team sports, but Tiger Woods victory at the Masters was voted The Associated Presss top sports story of the year. Its importance may come to be considered greater than his 1997 Masters victory, or his U.S. Open wins at Pebble Beach in 2000 and Torrey Pines in 2008. And as a comeback from adversity, Woods first major victory in 11 years at least rivals and arguably surpasses not only Ben Hogans 1950 U.S. Open, but ANY sports comeback ever. It was extra special.

But so much else happened in 2019. What to make of the rest?

Well, lets start with Woods. Its easy to forget that a lot of things had to go just right on Sunday for Tiger to win at Augusta. And that as much as the place is considered his sweet spot, he hadnt won there since 2005. For me, the singular moment that meant more going forward was the Zozo Championship in November. Not because it became Woods record-tying 82nd career. And despite the tournament being a limited field, off-season event over a short golf course in a faraway land.

Was there any doubt? For our No. 1 Storyline of the Year, we look back on Tiger Woods' 15th major title at the Masters Tournament.

It was the WAY that Tiger played with a return to an ease and smoothness in his action that not only recalled much earlier days, but which promises repeatability and consistency. As well as on the right occasions dominance.

Next on the hit parade the education of Rory McIlroy. The four-time major winner added important elements to his game namely better putting and overall ball control to set the foundation for another sustained run of greatness in his 30s.

But it was also a year of searching. McIlroy came into 2019 reflective and open to new ideas. He said meditation, juggling and several self-help books had led him to decide that he would no longer allow my score to define who I am as a person. His consistency improved and he impressively won The Players in March. But McIlroy also had several flattish Sundays with chances to win, and the Masters where he continues to chase the career Grand Slam didnt go so well.

Prior to the U.S. Open, McIlroy roared to a seven-shot win in Canada. But he tied for ninth at Pebble Beach. Expectations were again high at Portrush, a short car ride from his boyhood home and where he had shot the course record of 61 at age 16. He opened The Open with a nervous 79 and missed the cut. The next week he got boat-raced by winner Brooks Koepka in a final Sunday pairing at the WGC-FedEx in Memphis.

It was again time to reassess.

After winning the FedExCup at East Lake, this time outplaying Koepka in the last group in what he would later call the highlight of his year, McIlroy revealed having committed to a harder and more self-aware competitive edge.

I think one of the biggest things is sometimes Ive tried to treat Sundays the same as a Thursday or Friday, and theyre not, said McIlroy, who would go on to win WGC-HSBC in Shanghai in November for his fourth victory of the year. Ive gone into them maybe a little too relaxed, but its not the same, and its about trying to get yourself in the right mindset. I guess thats the ultimate compliment I can give Brooks is that I wanted to be a little bit more like him.

McIlroy on Koepka rivalry: Feels good to take down No. 1

Speaking of Big Game Brooks, his ruthless march through the major championships since 2017 has been undervalued. In the last 30 years, only Woods, McIlroy and Nick Faldo have had such prolonged periods of excellence in the biggest events.

This year, Koepka showed true dominance in building a seven-stroke lead through three rounds in his victory at the PGA at Bethpage. That he bookended that performance with seconds at the Masters and at the U.S. Open got short shrift. And after he finished fourth at Portrush, when his putter uncharacteristically failed him (and he was being bothered by a torn patella tendon in his left knee that required stem cell treatment and from which he is still recovering), too many acted as though his reign had ended.

That impression was strengthened when McIlroy was chosen as PGA Tour Player of the Year by a vote of his peers. In the last couple of years, Koepka has used relatively small slights for fuel. But going into 2020 and turning 30 in May, he will be on a mission to strengthen his hold on world No. 1 and outdo McIlroy in the process. Koepka betrayed some saltiness in October by pointing out that, Ive been out here for what, five years. Rory hasnt won a major since Ive been on the PGA Tour. So I dont view it as a rivalry.

Sounds like a rivalry.

Although Jon Rahm, who enters 2020 at No. 3 in the world, is expected to intrude.

The 25-year-old Spaniard earns the description beast in the same way as team sport athletes who appear physically overwhelming. Along with his nine combined victories on the PGA and European tours, Rahm has also validated his combination of power and touch with a relentless consistency in his first 89 official worldwide professional starts, Rahm has 44 top-10s, only one less than Woods in his first 89. As he continues to mature and he got married just this month expect a calmer, more controlled Rahm to be even more dangerous.

In the womens game, Jin Young Ko was by far the best player of the year, winning two majors and two other events in only her second season on the LPGA tour. In a gracious acceptance speech for year-end honors at the tours awards banquet, the 24-year-old South Koreans accented, but precise English reflected the same discipline and exactitude that is so evident in her game. The current Rolex No. 1 knows thats been a precarious perch over the last decade in womens golf, and she seems determined to change the cycle. This is not the end, she told the gathering, but only the beginning.

Ok, thats the highest profile stuff. But there was also a pervasive theme that permeated 2019. In so many ways, it was an extraordinarily feel-good year.

Usually in these end-of-the-year assessments, what sticks with me most and reinforces my generally tragic sense of competitive golf are the deeply wounding, self-induced losses brought on by late implosions. You know, Phil Mickelson at Winged Foot, Adam Scott at Royal Lytham & St. Annes, and Jordan Spieth at the 2016 Masters with plenty of other examples to stuff into the hurt locker. But as I remember 2019, only two players caused such sadness, Francesco Molinari at the Masters and Lizette Salas at the Womens British Open. Molinari, the seemingly unflappable ball-striking machine led by two strokes on the 12th tee Sunday at the Masters before mishitting an 8-iron into Raes Creek, opening the door for Woods. Salas, who played the best golf of her life with a closing 65 at Woburn, missed a 5-foot birdie putt on the 72nd hole, and then watched Hinako Shibuno win it with a 20-footer.

Instead of a bevy of heartbreak, we got a full complement of Capra-esque moments.

Winning putt: Pettersen clinches the Solheim Cup for Europe

Suzann Pettersen, after making an 8-footer on the final green in the last match that spelled the difference between winning and losing the Solheim Cup, announced her retirement at age 38. One of the great walk-offs ever in professional sports. Pettersen said she reached the decision spontaneously with the thought, This is it. This is the peak.

Shane Lowry, as an underachiever scarred by a Sunday failure at the 2016 U.S. Open, shouldering the immense mental load before thousands of home fans in a land that hadnt held the Open Championship since 1951, and winning by six. The panorama on Portrushs 72nd hole, with fansrunning up the fairway behind Lowry, some waving Irish flags in the rain amid a constant roar, was one of pure cathartic release.

Shibuno winning the Womens British Open at Woburn in her first professional tournament outside Japan. A babe in the woods at 20, she was bolstered by innocence and a constant, infectious smile, even as she four-putted early in the final round. Shibunocaught fire and closed with a 31 on the final nine, her final putt rammed in with a blissful freedom, to become the second Japanese player to win a major championship.

The scene at the inaugural Augusta National Womans Amateur, where the image of women striding the hallowed grounds was a transformative moment for the game. The impressive brand of head-to-head power golf played by winner Jennifer Kupcho and runner-up Maria Fassi was the icing on the cake.

The effervescent Helen Alfreddson winning the second U.S. Senior Womens Open at Pine Needles, the most joyous, about time and appreciated championship in golf. Love of the game is never more palpable than among too-long-ignored 50-and-over LPGA veterans, and Alfreddsons passion and exuberance spoke for them all.

Cameron Champ won the Safeway Open in October while dedicating his play to his gravely ill African-American grandfather, Mack, who started him in the game. The 24-year-old bombers calm as he garnered his second victory was reminiscent of Ben Crenshaws march to the 1995 Masters after being a pallbearer at the funeral of his teacher, Harvey Penick, earlier that week.

In the most exciting finish of the year, Matthew Wolff he of the fascinatingly powerful swing and unofficial leader of the games latest youth movement in only his third pro start, won the 3M Championship with an eagle on the 72nd hole to beat Bryson DeChambeau, who had also eagled the last, by one.

Finally and excuse my darkness Koepka and Rahm saving big victories after blowing huge Sunday leads. For some reason, nothing makes me happier (or more accurately relieved) than seeing a player who has gone from the zone to full meltdown, and then reverse what suddenly looks like his or her inevitable and awful fate in the nick of time. Koepka dug to the very bottom of his deep reservoir of poise to do it at Bethpage after four straight bogeys on the final nine had him lose all but one of his seven-stroke lead. Rahm had a five shot lead with 10 to play at the DP World in Dubai, but it was all gone thanks especially to a couple of knuckleheaded three-putts from inside 25 feet when he reached the 72nd hole. Hell remember that birdie with a smile and a shudder for the rest of his life.

Adding additional poignancy to our main theme, it was also the year of journeymen each capable, but with a history of struggle at the highest level seizing the day.

There is a fine line between success and slump in professional golf. It took only one swing to send Brendon Todd over that line and years to make it back.

Brendan Todd ran away with this category, returning from nearly four years in the wilderness that included a stretch of missing 37 of 41 cuts, to win back-to-back at Bermuda and Mayakoba, and then nearly won again at the RSM. The 34-year-old, who won the Byron Nelson in 2014, came down with a nightmare dose of the swing yips (the lose-it-way-right strain) that by late-2018 had him on the verge of giving up pro golf and opening a pizza franchise. Instead, Todd got some help from swing coach and former player Bradley Hughes and pulled off one of the great turnarounds in golf history.

And consider this roll call of others who went through storybook lost-and-found cycles to convert a week of magic into first victories that take them into 2020 with transformed lives: Max Homa (Wells Fargo Championship), JT Poston (Wyndham Championship), Nate Lashley (Rocket Mortgage), Lanto Griffin (Houston Open), Tyler Duncan (RSM Classic), Adam Long (Desert Classic). Inspirations all.

And at the risk of belaboring the feel-good point, it seemed that just about every level of pro golf ended the year on a happy note.

At the PGA Tours finale at East Lake, McIlroy spread much joy in Ponte Vedra, with one fell swoop validating the wisdom of the Tours more compressed and earlier finishing schedule, getting the new staggered start scoring system at the Tour Championship off on the right foot, and winning in the final group in another showdown with Koepka.

The LPGAs season ended on a high note with Sei Young Kim making a 22-foot birdie putt on the last hole to win the richest first-place prize ever in the womens game $1.5 million at the CME Group Tour Championship. A new format had been questioned for seeming to put sheer money over an equitable reward for season-long performance, but Kims stature as a top player and the cliffhanger nature of her victory over Charley Hull made for a satisfying result.

The PGA Tour Champions season ended with a bang when Jeff Maggert holed out from 123 yards for eagle to win the Charles Schwab Cup Championship in sudden-death.

And at the last big event of the year, the Presidents Cup, Woods was fittingly triumphant as both captain and player. And, as he has done more with age, a strong display of emotion spread the joy.

So finally, did something happen that set the tone for all this happiness? Was there a beginning?

Amy Bockerstette, a 20-year-old golfer with Down syndrome, got to play the iconic 16th hole at the Waste Management Phoenix Open and made par with Gary Woodland watching.

To say there wasnt would be to underestimate the impact of Amy Bockerstette, a 20-year-old collegiate golfer and Special Olympics athlete with Down syndrome, who in January played the 16th hole with Gary Woodland at the pro-am of the Waste Management Phoenix Open. Ill admit it, tears fill my eyes each time I watch the 2-minute and 50-second video, which has reached double-digit million views.

Seeing the way Bockerstette, clearly thrilled to meet her playing partners, Woodland and Matt Kuchar, reveled so genuinely as the center of attention on golfs iconic stadium hole, and then stepped up, assertively telling herself, I got this, is irresistible. She hit a good tee shot, followed with a deft bunker shot, and then, again repeating her mantra out loud, drilled the 10-footer for par with Nicklausian poise.

One guess at the phrase Woodland told himself before pulling off the shot of the year a perfectly clipped 60-degree wedge off the 17th green at Pebble Beach that carried and spun to within 4 feet and a crucial par.

Said Woodland of Bockertette: Theres nobody that Ive seen be in the moment as much as she is.

In a particularly feel-good year, it might have been the most extra special moment of all.

View original post here:
All the feels: From start to finish, a year of emotional stories - Golf Channel

Brain tumor organoids may be key to time-sensitive treatments for glioblastomas – Science Codex

PHILADELPHIA --Lab-grown brain organoids developed from a patient's own glioblastoma, the most aggressive and common form of brain cancer, may hold the answers on how to best treat it. A new study in Cell from researchers at Penn Medicine showed how glioblastoma organoids could serve as effective models to rapidly test personalized treatment strategies.

Glioblastoma multiforme (GBM) remains the most difficult of all brain cancers to study and treat, largely because of tumor heterogeneity. Treatment approaches, like surgery, radiation and chemotherapy, along with newer personalized cellular therapies, have proven to slow tumor growth and keep patients disease-free for some periods of time; however, a cure remains elusive.

"While we've made important strides in glioblastoma research, preclinical and clinical challenges persist, keeping us from getting closer to more effective treatments," said senior author Hongjun Song, PhD, Perelman Professor of Neuroscience in the Perelman School of Medicine at the University of Pennsylvania. "One hurdle is the ability to recapitulate the tumor to not only better understand its complex characteristics, but also to determine what therapies post-surgery can fight it in a timelier manner."

Co-senior authors include Guo-li Ming, MD, PhD, Perelman Professor of Neuroscience, and Donald O'Rourke, MD, the John Templeton, Jr., MD Professor in Neurosurgery, and director of the GBM Translational Center of Excellence at Penn's Abramson Cancer Center.

Lab-grown brain organoids -- derived from human pluripotent stem cells or patient tissues and grown to a size no bigger than a pea -- can recapitulate important genetic composition, brain cell type heterogeneity, and architecture, for example. These models are allowing researchers to recreate key features of patients' diseased brains to help paint a clearer picture of their cancer, and allowing them to explore ways to best attack it.

What makes organoids so attractive in GBM is timing and the ability to maintain cell type and genetic heterogeneity. While existing in vitro models have added to researchers' understanding of the biological mechanisms underlying the cancer, they have limitations. Unlike other models, which need more time to exhibit gene expression and other histological features that more closely represent the tumor, brain tumor organoids developed by the research group grow into use much more rapidly. That's important because current treatment regimens are typically initiated one month following surgery, so having a road map sooner is more advantageous.

In the new study, the researchers removed fresh tumor specimens from 52 patients to "grow" corresponding tumor organoids in the lab. The overall success rate for generating glioblastoma organoids (GBOs) was 91.4 percent, with 66.7 percent of tumors expressing the IDH1 mutation, and 75 percent for recurrent tumors, within two weeks. These tumor glioblastoma organoids can also be biobanked and recovered later for analyses.

Genetic, histological, molecular analyses were also performed in 12 patients to establish that these new GBOs had largely retained features from the primary tumor in the patient.

Eight GBO samples were then successfully transplanted into adult mouse brains, which displayed rapid and aggressive infiltration of cancer cells and maintained key mutation expression up to three months later. Importantly, a major hallmark of GBM -- the infiltration of tumor cells into the surrounding brain tissue -- was observed in the mouse models.

To mimic post-surgery treatments, the researchers subjected GBOs to standard-of-care and targeted therapies, including drugs from clinical trials and chimeric antigen receptor T (CAR-T) cell immunotherapy. For each treatment, researchers showed that the organoid responses are different and effectiveness is correlated to their genetic mutations in patient tumors. This model opens the possibility for future clinical trials for personized treatment based on individual patient tumor responses to various different drugs.

Notably, the researchers observed a benefit in the organoids treated with CAR T therapies, which have been used in ongoing clinical trials to target the EGFRvIII mutation, a driver of the disease. In six GBOs, the researchers showed specific effect to patient GBOs with the EGFRvIII mutation with an expansion of CAR T cells and reduction in EGFRvIII expressing cells.

"These results highlight the potential for testing and treating glioblastomas with a personalized approach. The ultimate goal is to work towards a future where we can study a patient's organoid and test which CAR T cell is going to be the best against their tumor, in real time." O'Rourke said. "A shorter-term goal, given the heterogeneity of glioblastomas, is that in vitro testing of various therapeutic options may also help refine patient enrollment in clinical trials, by more accurately defining mutations and selecting the appropriate, available targeted therapies for each."

Here is the original post:
Brain tumor organoids may be key to time-sensitive treatments for glioblastomas - Science Codex

Michael Schumacher update: How is Michael Schumacher doing – six years on? – Express.co.uk

Speaking to Shes Mercedes magazine last month, she said: He is in the best of hands right now and we are doing everything we can to help him.

Try to understand that we follow Michaels desire to keep his health a secret.

You can be sure that he is in the very best of hands and that we are doing everything humanly possible to help him.

Please understand if we are following Michaels wishes and keeping such a sensitive subject as health, as it has always been, in privacy.

Michael Schumachers fans have honoured Corinnas request, as Reiner Ferling, chairman of the Kerpen fan club, said they would provide all kinds of support.

He said: Unfortunately, the time has come again, the sixth anniversary of Michaels accident is coming around.

Six years full of hope that Michael will one day go out in public again. We know that Michael is in good hands, that he gets love, security and confidence.

Michael can count himself lucky to have such a strong family behind him.

Visit link:
Michael Schumacher update: How is Michael Schumacher doing - six years on? - Express.co.uk

Health care in America is dysfunctional but its lack of transparency is downright dangerous – NBC News

Wow, you survived cancer? What's your secret to health care?

As absurd as that sounds, its a question many Americans who get sick are still asking as we ring in the year 2020. Getting health care in this country is still so circuitous it often does feel like a secret a maze deciphered in private that's never quite mastered. The reward for solving it? Perhaps your life; perhaps the loss of your life savings. And thats if youre lucky.

Even with the Affordable Care Act, almost 30 million are without health insurance in the U.S. And if youve perused plans on the ACA marketplace, youll know why. Theyre pricey, and a new year brings fears that insurance premiums are once again rising. (Who knew the inflation rates on a pap smear were that high?!) Meanwhile, 14 Republican-led states are still refusing to expand Medicaid as stipulated in the ACA, even though the federal government would pay for 90 percent of the cost. Why? Something about repeal and replace or socialism. Its hard to keep track.

Even with the Affordable Care Act, almost 30 million are without health insurance in the U.S. And if youve perused plans on the ACA marketplace, youll know why.

I traveled to three states, each with their own unique health care access challenges, for my new MSNBC special "Red, White, and Who? Between Texas, New York and Utah there are major differences in how easy it is to see a doctor without going bankrupt. But every single person I spoke with regardless of job, socioeconomic status or even political affiliation had one identical anxiety: healthcare in one of the most advanced countries in the world is ridiculously, hopelessly complicated.

Get the think newsletter.

Im retired, but I feel like a have a job, Larry Chiuppi told me sitting outside at an RV park in Houston, blocks from one of the top cancer treatment hospitals in the country. Larry has been caring for his wife Nancy Raimondi, who has blood cancer, for over a year. During that time, he himself was diagnosed with prostate cancer. Even with her Medicare and his private health plan under the ACA, navigating the billing systems for the endless hospital visits, specialists and tests each with their own separate charges requires a huge amount of time and vigilance. He tells me they once got a $14,000 bill for a stem cell transplant because someone forgot to link Nancys Medicare. Larry imagined many people wouldve just tried to pay it. And most Americans dont have a retirees free time and Larrys persistence to help them through the bureaucracy, an added burden of getting well.

We also dont all have a mother like Sandra Stein. She and her family live in New York, a state where the uninsured population is less than five percent, and 6.5 million are on Medicaid. I met Sandra on a street corner in upper Manhattan, where activists were flyering for the New York Health Act, a bill that would give every New Yorker state-funded care. Sandra believes in single-payer healthcare because she has experienced the mind-numbing labyrinth that is the private insurance system firsthand.

When her son was nearly three, he developed a rare neurological disease that left him unable to walk or speak. At the time, she and her husband had private insurance, which was relatively good insurance, according to Sandra. But that didnt make things easier. When they first went to the hospital in an ambulance, the doctors there didnt take their insurance even though the hospital did. Her son ultimately stayed in three different hospitals over the course of 15 months.

When we got home it was my job to figure out the pile of bills and the collections threats, she told me. Its been eight years, but Sandras voice cracked like the memory happened yesterday. I couldnt imagine how hard it mustve been to be afraid for your childs life while collections agents breathed down your neck. Sandra says the billing department sought her out even while her son was in the ICU, and that there were so many billing errors that she ultimately asked for an audit.

And yet, Sandra, Larry and Nancy are the lucky ones. They have health insurance, and they have the time and resources to be able to make their way through the bureaucratic hall of mirrors and toward a fighting chance at getting well.

Its this cruel opacity of the private insurance system, on top of the rising monthly costs of just having a plan, that can be the difference between life and death. And it keeps a surprising number of Americans away from the system altogether. Like a rodeo cowboy I met in Texas, whose story youll just have to watch (Im not spoiling it all!). Its also led Americans like Sandra to believe that a massive simplification of our health care system is far overdue.

For many, that simplification comes in the form of cutting out the profit motive and moving toward government-funded insurance, like Medicare for All, which Big Pharmas enemy number one Sen. Bernie Sanders and I hashed out over bagels in a New York City deli.

Ultimately what became clear through my travels is that healthcare in America is often overpriced and even dysfunctional, but its the lack of transparency that can be the most insidious. You pretty much have to be a health care policy expert, or have a loved one who can quit their job to become one, in order to ensure proper help.

Its also strange that in a country that loves the free market as much as we do, we the consumer have no idea how much anything costs when we walk into a hospital. Why would we? Our health is priceless, so we are simply at the mercy of an ineffective system. That is, unless we fight for something different.

Red, White, and Who premieres on MSNBC on Dec. 29 at 9 p.m. E.T.

Francesca Fiorentini is journalist and comedian. She is the host of "Red, White and Who?" on MSNBC and Newsbroke on AJ+. Follow her @franifio.

See the article here:
Health care in America is dysfunctional but its lack of transparency is downright dangerous - NBC News

Sickle cell patient is pain free after geneediting trial altered her DNA – The Times

Sickle cell disease is a genetic condition in which red blood cells, which should be circular, adopt a crescent shape and are sticky and rigidALAMY

The first patients to receive gene-editing treatments for inherited blood diseases will enter the new year free of agonising symptoms.

The experiments suggest that altering DNA could treat sickle cell disease (SCD) and beta thalassemia, conditions both caused by faulty genes that hamper the bloods ability to carry oxygen.

The companies behind the trials said that a patient in the US with SCD had been well since July. A thalassemia patient in Germany had been free of symptoms for nine months. Previously she had 16 blood transfusions a year.

British patients could be offered similar experimental therapies next year. The treatment for both conditions involved a high-precision gene-editing tool called Crispr-Cas9. It was used to alter the DNA of some of the cells of Victoria

Want to read more?

Subscribe now and get unlimited digital access on web and our smartphone and tablet apps, free for your first month.

Read more here:
Sickle cell patient is pain free after geneediting trial altered her DNA - The Times

5-year-old UK boy receives potentially life-saving cancer treatment in Singapore – The Independent

- Advertisement -

Singapore A young boy from the United Kingdom received treatment for leukaemia in Singapore on Christmas Eve with a procedure that could possibly save his life.

Five-year-old Oscar Saxelby-Lee was diagnosed with a particularly aggressive form of the cancer called T-cell acute lymphoblastic leukaemia over the Christmas holidays last year.

He received chemotherapy and stem-cell treatment back home over the course of the year but the cancer returned in September.

In March, the boy had been featured both on the BBC and in The New York Times when thousands of people responded to a campaign launched by his primary school. They signed the stem cell register and donated bloodto see if a match could be found for him, as a stem cell transplant had been recommended but neither of his parents was a close enough match.

- Advertisement -

Three matches were found by the end of March, and in May, the transplant was scheduled.

The boys health improved temporarily but by September his family announced that the cancer had recurred.

Oscars friends, family, community and even complete strangers rallied around him again, and raised 500,000 (approximately S$880,000) through crowdfunding to bring him to Singapore for the treatment, which is not available in the UKs National Health Service (NHS).

Ms Olivia Saxelby, the boys mother, told bbc.com that the treatment, called CAR-T therapy, which reprograms the cells in patients immune systems, is designed for individual patients. The reprogrammed cells then are used to target the cancer cells.

Within a week, Ms Saxelby said, doctors will determine whether the procedure was effective.

She called their journey since Oscar received treatment an emotional ride.

The Saxelby-Lee family has been in Singapore from the middle of last month and could stay for as long as half a year.

Another young boy from the UK, Zac Oliver, received the same treatment in the United States in March this year. He has been declared free from cancer.

Zac was diagnosed with acute lymphoblastic leukaemia in May last year and was brought to the Childrens Hospital of Philadelphia by November, after a similar crowdfunding effort also raised 500,000 for his treatment and travel.

The boys CAR T-cell therapy lasted 17 weeks and he was given a 60 to 80 per cent chance of survival. In March, however, he said in a video posted on Facebook: Guess what everyone, I have no cancer.

Zacs rare condition affects only one out of every 200 childhood leukaemia patients around the world. -/TISG

Read related:Toshiba says its device tests for 13 cancer types with 99% accuracy from a single drop of blood

Toshiba says its device tests for 13 cancer types with 99% accuracy from a single drop of blood

- Advertisement -

Here is the original post:
5-year-old UK boy receives potentially life-saving cancer treatment in Singapore - The Independent

The best beauty products and spa treatments for New Year’s Eve parties – Evening Standard

The hottest luxury and A List news

New Years Eve is around the corner - and if your skin is lackinglusterafter spending most of the Christmas season boozing, meet your quick-fix beauty products.

Get the glow

(CharlotteTilbury)

CharlotteTilburysFlawless Finish foundation is my skin saviour. This is my go-to for those days that I need model-worthy skin with minimal effort. I don't need to mess around with concealer since the foundation has enough coverage without looking heavy. Not only does it look amazing, but it also comes with some incredible benefits: moisture levels are boosted by 216 percent, exposure to pollutants isreduced, it's sweat-proof, humidity-proof, water-proof and transfer-resistant and comes with wrinkle-reducing qualities.

(CharlotteTilbury)

Apply it withTilburysfoundation brush for a truly naturally airbrushed finish.

(AugustinusBader)

If you're looking for a more in-depth reboot for your skin in 2020,AugustinusBadersrange is ano-brainer. There's an incredible amount of science that goes behind these miracle creams - ProfessorAugustinusBaderis among the worlds leading scientific minds in stem cell biology.

No wonder natural beauties like Naomi Campbell, Alexa Chung, Demi Moore and Dakota Johnson are devoted fans and the range has picked up prestigious awards. I would consider myself a skincare aficionado with over ten years in the fashion and entertainment industry, and I can assure you theres not one single skincare product I've tried that's as transformative asBadersproduct The Cream. It's an understated, refined transformation - more Frenchfashionistathan Beverley Hills housewife. Afterusing The Cream I began receiving unsolicited compliments from strangersonly a week into its use.

(The Dorchester)

If you would rather see afacialistor top up your new skin care routine with the help of an expert, dont fret - your 2020 prescription for a fresh-faced glow comes in the formAdeelaCrowns top-of-the-line facials at The Dorchester. I'm a huge fan ofmicrocurrentfacials as facial features are drastically lifted and sculpted and Crowns Supersculpt treatment harnesses this technology to impressive results. Just as wow-worthy is her signature Skincredible treatment - using a method called Skindance, which combines elements of Chineseguasha, Hungarian massage and Tanaka acupressure to shift deep-seated toxins and encourage blood flow, sculpting the facial contours. Appointments are in demand, however, usually Crown is in on Thursdays, Fridays and the first and second Saturday of each month

Wow with those brows

They say that brows frame the eyes and highlight your best features - so why wouldn't you pay them extra attention? LA brand Hourglasscreated the Arch Brow Sculpting Pencil - a clever combo of powder, wax and pencil. You are able to recreate fine brow hairs easily with the pointed tip and the flat edge is designed to subtly shade for an effect that is very natural. Use a light hand and simply set with a clear gel for brows that wow.

If you cannot be bothered fiddling with your brows almost daily, why dont you treat yourself to a more (semi-)permanent solution?DaxitaVaghelais Londons top eyebrow technician and she has tended to the brows and lashes of stars JessicaChastain,LupitaNyongo, Michelle Pfeiffer and Sandra Oh to name but a few.

(Daxita)

Microbladingmay conjure thoughts of exaggerated slugs resting above your eyes, however,Daxitasarent your cliched Essex-brows at all - she can create the most natural and subtle effect with her experttechnique. Its almost impossible to tell which eyebrow hairs are your own and which areDaxitascreations. She also takes time to listen to what type of effect you wish to achieve and errs on the side of caution - because if you wish to go for something more dramatic this can always be added on later. This cautious and meticulous approach is why the treatment requires a total of three visits to achieve the end product. This may seem like quite the commitment, but if you spend time perfecting your brows almost daily - this really is an investment to save a lot of effort over the course of the year.

Tame that mane

When it comes to styling your own hair, it is always a battle with tangles, heat damage and lack of technique. Especially on New Years Eve, there's no time for any of that, so this is when DysonsAirWrapstyler - the Rolls Royce of hair tools - comes to the rescue. It's the closest thing to becoming your own hairstylist. In fact, it is a product loved bystylist to the stars Jen Atkin.

(Courtesy Photo)

Six years of research and development went into creating this state-of-the-art styling tool that specialises in a smooth finish without extreme heat. It all comes down to Dysons ability to manipulate airflow - something the company is well versed in. TheAirwrapcomes with six different attachments, so whether you want to bring in the New Year with voluminous curls, beach waves or a smooth and straight do - the sky is the limit and there are plenty oftutorials guiding you to achieving hair perfection all year round. It is also the lazy girls best friend; in the morning I tend to dampen the hairs framing my face and a few sections at the back and then work them using a couple sweeps with theAirwrapand - voila! Salon-fresh locks created in minutes.

(Courtesy Image)

If you would prefer to try theAirWrapin person first, Dysons new Beauty Lab which is situated above the Dyson Demo Store on Oxford Street is the perfect place to experience the array of different styles that can be achieved with the near-magical tools.

(Courtesy Image)

You can book a 45-minute appointment online or try your luck with a walk-in appointment. It is a really useful way to learn how to make the most out of their hair tools with the help of professional stylists. If you do decide to take the plunge and purchase theAirWrap(and banish bad hair days in the process) you can also personalise yourAirWrapcase with your initials when purchasing it in store.

Post-party prescription

Surely not the most exciting part of your party regime, yet easily the most underrated is caring for your clothes and accessories after an epic night out. Aftercare naturally fits within the sustainability movement, as taking proper care of your clothing can lengthen their life. Contrary to popular belief, garments that lose colour or shape are often not worn out - they are either washed incorrectly or simply washed too often. Clothes that are properly maintained with the correct care will last.

(Courtesy Image)

This is why I love the compact steamers fromSteameryStockholm. I much prefer steaming to ironing as it takes up way less space (those bulky ironing boards are my worst nightmare) works on all kinds of fabrics, and the steam also reduces bad odours and removes shallow dirt. It is also super easy to bring on a weekendtrip. Steaming is also more environmentally friendly, since you dont have to wash the clothes that only need to be refreshed. The Swedish brand also offers electric fabric shavers to get rid of unsightly pilling. The companys innovative approach extends tocustomer service via an excellent discussion forum.

(Courtesy Image)

In some instances, steaming might not be enough to solve all your aftercare woes - especially if your wild night resulted in some lost sequins from yourKitrimidi-dress or your suedeshoes were trampled on. This is where Hicks of Chelsea has you covered.

Hicks offers extensive repairs for shoes, clothing and accessories (including watches!) as well as very high quality, non-aggressive eco-friendly dry cleaning. They also take care of laundry and household items, offer alterations and even key cutting. Part of the Pavilion Road village inKnightsbridge, Hicks of Chelsea is every bit the chic neighbourhood dry cleaners youd expect - and more. Their ethos is to be kind to your clothing as well as the environment. There's even a complimentary collection and delivery service offered by Hicks for those living or working in London: the Hicks driver will collect items from the most convenient location for you and deliver them back, packaged and ready for safe return to your wardrobe.

Link:
The best beauty products and spa treatments for New Year's Eve parties - Evening Standard